Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ceftriaxone | The risk or severity of adverse effects can be increased when Calcium pangamate is combined with Ceftriaxone. |
| Deferiprone | The serum concentration of Deferiprone can be decreased when it is combined with Calcium pangamate. |
| Dobutamine | The therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium pangamate. |
| Dolutegravir | The serum concentration of Dolutegravir can be decreased when it is combined with Calcium pangamate. |
| Eltrombopag | The serum concentration of Eltrombopag can be decreased when it is combined with Calcium pangamate. |
| Estramustine | Calcium pangamate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcium acetate | The risk or severity of adverse effects can be increased when Calcium pangamate is combined with Calcium acetate. |
| Digoxin | Calcium pangamate may increase the arrhythmogenic and cardiotoxic activities of Digoxin. |
| Acetyldigitoxin | Calcium pangamate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin. |
| Deslanoside | Calcium pangamate may increase the arrhythmogenic and cardiotoxic activities of Deslanoside. |
| Ouabain | Calcium pangamate may increase the arrhythmogenic and cardiotoxic activities of Ouabain. |
| Digitoxin | Calcium pangamate may increase the arrhythmogenic and cardiotoxic activities of Digitoxin. |
| Oleandrin | Calcium pangamate may increase the arrhythmogenic and cardiotoxic activities of Oleandrin. |
| Cymarin | Calcium pangamate may increase the arrhythmogenic and cardiotoxic activities of Cymarin. |
| Proscillaridin | Calcium pangamate may increase the arrhythmogenic and cardiotoxic activities of Proscillaridin. |
| Metildigoxin | Calcium pangamate may increase the arrhythmogenic and cardiotoxic activities of Metildigoxin. |
| Lanatoside C | Calcium pangamate may increase the arrhythmogenic and cardiotoxic activities of Lanatoside C. |
| Gitoformate | Calcium pangamate may increase the arrhythmogenic and cardiotoxic activities of Gitoformate. |
| Acetyldigoxin | Calcium pangamate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigoxin. |
| Peruvoside | Calcium pangamate may increase the arrhythmogenic and cardiotoxic activities of Peruvoside. |
| Grepafloxacin | Calcium pangamate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Enoxacin | Calcium pangamate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pefloxacin | Calcium pangamate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ciprofloxacin | Calcium pangamate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Trovafloxacin | Calcium pangamate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nalidixic acid | Calcium pangamate can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rosoxacin | Calcium pangamate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cinoxacin | Calcium pangamate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lomefloxacin | Calcium pangamate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gatifloxacin | Calcium pangamate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norfloxacin | Calcium pangamate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gemifloxacin | Calcium pangamate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ofloxacin | Calcium pangamate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sparfloxacin | Calcium pangamate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Temafloxacin | Calcium pangamate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fleroxacin | Calcium pangamate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Technetium Tc-99m ciprofloxacin | Calcium pangamate can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Garenoxacin | Calcium pangamate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nemonoxacin | Calcium pangamate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Flumequine | Calcium pangamate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Enrofloxacin | Calcium pangamate can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Orbifloxacin | Calcium pangamate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sarafloxacin | Calcium pangamate can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Difloxacin | Calcium pangamate can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pazufloxacin | Calcium pangamate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Prulifloxacin | Calcium pangamate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delafloxacin | Calcium pangamate can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sitafloxacin | Calcium pangamate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Oxolinic acid | Calcium pangamate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rufloxacin | Calcium pangamate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pipemidic acid | Calcium pangamate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Strontium ranelate | The serum concentration of Strontium ranelate can be decreased when it is combined with Calcium pangamate. |
| Doxycycline | The serum concentration of Doxycycline can be decreased when it is combined with Calcium pangamate. |
| Lymecycline | The serum concentration of Lymecycline can be decreased when it is combined with Calcium pangamate. |
| Clomocycline | The serum concentration of Clomocycline can be decreased when it is combined with Calcium pangamate. |
| Oxytetracycline | The serum concentration of Oxytetracycline can be decreased when it is combined with Calcium pangamate. |
| Demeclocycline | The serum concentration of Demeclocycline can be decreased when it is combined with Calcium pangamate. |
| Tetracycline | The serum concentration of Tetracycline can be decreased when it is combined with Calcium pangamate. |
| Metacycline | The serum concentration of Metacycline can be decreased when it is combined with Calcium pangamate. |
| Minocycline | The serum concentration of Minocycline can be decreased when it is combined with Calcium pangamate. |
| Sarecycline | The serum concentration of Sarecycline can be decreased when it is combined with Calcium pangamate. |
| Omadacycline | The serum concentration of Omadacycline can be decreased when it is combined with Calcium pangamate. |
| Penimepicycline | The serum concentration of Penimepicycline can be decreased when it is combined with Calcium pangamate. |
| Methyclothiazide | Methyclothiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. |
| Chlorthalidone | Chlorthalidone may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. |
| Bendroflumethiazide | Bendroflumethiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. |
| Metolazone | Metolazone may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. |
| Benzthiazide | Benzthiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. |
| Hydroflumethiazide | Hydroflumethiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. |
| Indapamide | Indapamide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. |
| Chlorothiazide | Chlorothiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. |
| Hydrochlorothiazide | Hydrochlorothiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. |
| Trichlormethiazide | Trichlormethiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. |
| Polythiazide | Polythiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. |
| Quinethazone | Quinethazone may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. |
| Cyclopenthiazide | Cyclopenthiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. |
| Epitizide | Epitizide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. |
| Triethylenetetramine | Calcium pangamate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcitriol | The risk or severity of adverse effects can be increased when Calcitriol is combined with Calcium pangamate. |
| Calcifediol | The risk or severity of adverse effects can be increased when Calcifediol is combined with Calcium pangamate. |
| Ergocalciferol | The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Calcium pangamate. |
| Cholecalciferol | The risk or severity of adverse effects can be increased when Cholecalciferol is combined with Calcium pangamate. |
| Paricalcitol | The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium pangamate. |
| Dihydrotachysterol | The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium pangamate. |
| Alfacalcidol | The risk or severity of adverse effects can be increased when Alfacalcidol is combined with Calcium pangamate. |
| Calcipotriol | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium pangamate. |
| Seocalcitol | The risk or severity of adverse effects can be increased when Seocalcitol is combined with Calcium pangamate. |
| Inecalcitol | The risk or severity of adverse effects can be increased when Inecalcitol is combined with Calcium pangamate. |
| Becocalcidiol | The risk or severity of adverse effects can be increased when Becocalcidiol is combined with Calcium pangamate. |
| Eldecalcitol | The risk or severity of adverse effects can be increased when Eldecalcitol is combined with Calcium pangamate. |
| 1alpha,24S-Dihydroxyvitamin D2 | The risk or severity of adverse effects can be increased when 1alpha,24S-Dihydroxyvitamin D2 is combined with Calcium pangamate. |
| Elocalcitol | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium pangamate. |
| Maxacalcitol | The risk or severity of adverse effects can be increased when Maxacalcitol is combined with Calcium pangamate. |
| Doxercalciferol | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium pangamate. |
| Vitamin D | The risk or severity of adverse effects can be increased when Vitamin D is combined with Calcium pangamate. |
| 1alpha-Hydroxyvitamin D5 | The risk or severity of adverse effects can be increased when 1alpha-Hydroxyvitamin D5 is combined with Calcium pangamate. |
| Tacalcitol | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium pangamate. |
| Previtamin D(3) | The risk or severity of adverse effects can be increased when Previtamin D(3) is combined with Calcium pangamate. |
| Isradipine | The therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium pangamate. |
| Diltiazem | The therapeutic efficacy of Diltiazem can be decreased when used in combination with Calcium pangamate. |